Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.

doi:10.1111/dom.70005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.

Diabetes, obesity & metabolism - 1 Nov 2025

Caruso Irene, Giordano Fiorella, Matichecchia Immacolata Ilaria, Di Gioia Ludovico, Di Molfetta Sergio, Cignarelli Angelo, Sorice Gian Pio, Natalicchio Annalisa, Laviola Luigi, Giorgino Francesco

Abstract excerpt

AIMS: Type 2 diabetes (T2D) is a heterogeneous disease, with varying pathogenetic mechanisms influencing treatment response. Glucagon-like peptide-1 receptor agonists (GLP-1RA) offer clear metabolic benefits in T2D, but interindividual variability in response is observed. This retrospective study investigated whether GLP-1RA effectiveness varies by T2D phenotypes (severe insulin-deficient diabetes [SIDD], severe...

Read the complete abstract on PubMed

Topics

Humans
Diabetes Mellitus, Type 2
Retrospective Studies
Female
Male
Phenotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Glucagon-Like Peptide-1 Receptor Agonists

Glycated Hemoglobin

Hypoglycemic Agents

Aged

Treatment Outcome

Italy

Blood Glucose

Source

Open in PubMed Open full text

Identifiers

PMID: 40785519
DOI: 10.1111/dom.70005
PMCID: PMC12515759

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.PMID 40785519Read ↗

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity Read ↗

Personalized therapy algorithms for type 2 diabetes: a phenotype-based approachSemantic proximity Read ↗

Comparison of clustering and phenotyping approaches for subclassification of type 2 diabetes and its association with remission in Indian population.Semantic proximity Read ↗

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesSemantic proximity Read ↗

Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.Semantic proximity Read ↗

Type 2 diabetes subphenotypes are associated with differential outcomes after metabolic and bariatric surgery: An international multicentre retrospective cohort study.Semantic proximity Read ↗

Heterogeneity of Treatment Effects of Glucose-lowering Drug Classes for Type 2 Diabetes: LEGEND-T2DM Network Real-World EvidenceSemantic proximity Read ↗

Cohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study – a prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetesSemantic proximity Read ↗

[Phenotypic Classification of Diabetes: A Personalized Approach for Pharmaceutical Practice].Semantic proximity Read ↗

GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes MellitusSemantic proximity Read ↗

Efficacy and Safety Among Second-Generation and Other Basal Insulins in Adult Patients with Type 1 Diabetes: A Systematic Review and Network Meta-AnalysisSemantic proximity Read ↗

Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.